BridgeMD
Compares treatment options for Non-small Cell Lung Cancer (NSCLC)
Official title A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
ClinicalTrials.gov ID: NCT07361497
What this study is testing
What is Pumitamig?
Pumitamig is an investigational medicine, being studied as a potential treatment for non-small cell lung cancer (nsclc).
Also referred to as BMS-986545.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participants must have a histologically- or cytologically-confirmed diagnoses of non-small cell lung cancer (NSCLC) with unresectable Stage III...
- Participants must have received at least 2 cycles of platinum-based concurrent chemoradiotherapy (a total dose of radiation of at least 54 Gy).
- Participants must have no progressive disease (PD) following treatment with concurrent chemoradiotherapy (CCRT).
- Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1.
You likely can't join if
- Participants with non-squamous histology must not have documented Epidermal Growth Factor Receptor (EGFR) and anaplastic lymphoma kinase (ALK)...
- Participants must not have an active autoimmune disease.
- Participants must not have significant cardiovascular impairment such as uncontrolled hypertension (despite optimal medical treatment), congestive...
- Participants must not have advanced/clinically significant lung disease (within 6 months prior to randomization) or history of interstitial lung...
- Participants must not have any prior anticancer therapy (outside of CCRT) for locally advanced Stage III disease.
- Other protocol-defined Inclusion/Exclusion criteria apply.
The study team makes the final eligibility decision.
Where it's taking place
- Daphne, Alabama, United States
- Chandler, Arizona, United States
- Golden, Colorado, United States
- Newark, Delaware, United States
- Ocala, Florida, United States
- Marietta, Georgia, United States
- Chicago, Illinois, United States
- Evanston, Illinois, United States
- Peoria, Illinois, United States
- Fort Wayne, Indiana, United States
- Lexington, Kentucky, United States
- Boston, Massachusetts, United States
- Detroit, Michigan, United States
- Maple Grove, Minnesota, United States
- Saint Paul, Minnesota, United States
- Columbia, Missouri, United States
- New York, New York, United States
- Westbury, New York, United States
- Winston-Salem, North Carolina, United States
- Akron, Ohio, United States
+ 213 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Daphne, Alabama, United States; Chandler, Arizona, United States; Golden, Colorado, United States; Newark, Delaware, United States; Ocala, Florida, United States; Marietta, Georgia, United States and 227 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.